Teichmann joins with deep experience across academic neuroscience, surgical robotics, clinical development and medical affairs.

She co-founded and helped scale Medical Microinstruments, where she served as Vice President of Clinical Development and Medical Affairs, and has subsequently worked with companies across neuromodulation, robotics and digital health.

“Robeauté brings together notable threads of my career: neuroscience, robotics and the clinical work required to translate ambitious technologies into meaningful options for patients in need. I look forward to progressing the evidence needed to bring the platform into first-in-human studies and, ultimately, to patients and healthcare systems at large.”

As Chief Clinical Officer, Hannah will lead Robeauté’s global clinical strategy and evidence-generation program, building on clinical progress to date with the company’s multidisciplinary team and its global neurosurgery and neuro-oncology partners. Particularly in Europe and the United States, where Robeauté is engaging with the FDA on the clinical and regulatory pathway for the platform.

“Not only are we developing a new device; we are building microrobotic infrastructure needed to establish an entirely new category of neuro-intervention. Hannah's expertise significantly strengthens our ability to build that infrastructure around regulators, clinicians, patients, and rigorous evidence.”‍

Bertrand Duplat, Co-Founder and CEO

“Hannah has the rare combination of scientific depth, founder scar-tissue and practical industry understanding of what it takes to bring a surgical robotic platform from an idea into clinical reality. Her perspective and experience will be fundamental as we move into the next stage.”

Joana Cartocci, Co-Founder and COO

Robeauté is building the infrastructure that will drive innovative treatments for brain disease. The technology is centered around a microrobot capable of diagnosing, treating and monitoring the brain.